Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats

(2018) Krit Jaikumkao et al.   DIABETES OBESITY & METABOLISM

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

(2018) Hussein Al Jobori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of cinnamic acid on memory deficits and brain oxidative stress in streptozotocin-induced diabetic mice

(2018) Ali Asghar Hemmati et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

GABA Regulates Release of Inflammatory Cytokines From Peripheral Blood Mononuclear Cells and CD4 + T Cells and Is Immunosuppressive in Type 1 Diabetes

(2018) Amol K. Bhandage et al.   EBioMedicine

Protective effects of γ-aminobutyric acid against H2O2-induced oxidative stress in RIN-m5F pancreatic cells

(2018) Xue Tang et al.   Nutrition & Metabolism

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

(2018) Julio Rosenstock et al.   DIABETES CARE

Fenofibrate attenuates fatty acid-induced islet β-cell dysfunction and apoptosis via inhibiting the NF-κB/MIF dependent inflammatory pathway

(2017) Shuang Zheng et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Challenges and issues with streptozotocin-induced diabetes – A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics

(2016) Sameer N. Goyal et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10–Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells

(2016) Tatiana Takiishi et al.   DIABETES

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice

(2016) Weiling Leng et al.   MEDIATORS OF INFLAMMATION

The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

(2016) Matthias Kern et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes

(2016) Sam Tsz Wai Cheng et al.   PLoS One

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

(2015) Arthur T. Sands et al.   DIABETES CARE

Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

(2015) Robert R. Henry et al.   DIABETES CARE

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)

(2015) T. R. Pieber et al.   DIABETES OBESITY & METABOLISM

Combination therapy for type 2 diabetes: dapagliflozin plus metformin

(2015) Xueying Tan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention

(2015) Aaron Michels et al.   PEDIATRIC DIABETES

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

Characteristics and Determinants of Partial Remission in Children with Type 1 Diabetes Using the Insulin-Dose-Adjusted A1C Definition

(2014) Aurore Pecheur et al.   Journal of Diabetes Research

Progress in immune-based therapies for type 1 diabetes

(2013) M. von Herrath et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Role of pancreaticβ-cell death and inflammation in diabetes

(2013) W. Quan et al.   DIABETES OBESITY & METABOLISM

Maturation of Human Embryonic Stem Cell-Derived Pancreatic Progenitors Into Functional Islets Capable of Treating Pre-existing Diabetes in Mice

(2012) A. Rezania et al.   DIABETES

The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions

(2012) Mohammed Bensellam et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Regeneration of Pancreatic Non-β Endocrine Cells in Adult Mice following a Single Diabetes-Inducing Dose of Streptozotocin

(2012) Yanqing Zhang et al.   PLoS One

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

(2011) Tom L. Van Belle et al.   PHYSIOLOGICAL REVIEWS

GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes

(2011) N. Soltani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss

(2010) Fabrizio Thorel et al.   NATURE

Oxidative stress and beta-cell dysfunction

(2010) Gisela Drews et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

In vivo reprogramming of adult pancreatic exocrine cells to β-cells

(2008) Qiao Zhou et al.   NATURE